Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of miR-101 in pheochromocytoma patients with SDHD mutation.

International journal of clinical and experimental pathology - 1 Jan 2015

Zong Ligeng, Meng Lizhen, Shi Ruhui

Abstract excerpt

This study aimed to screen the potential diagnostic biomarkers for distinguishing the malignant pheochromocytoma (PCC) from benign PCC. A total of 59 patients with PCC (benign and malignant) were enrolled in this study. The expression level of miRNAs in patients with different kind PCCs (healthy control, benign, malignant, malignant with or without SDHD mutation, adrenal and extra-adrenal) was analyzed using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Area Under Curve
Share to Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MicroRNAs

Share to Pheochromocytoma

Share to Real-Time Polymerase Chain Reaction

Share to ROC Curve

Share to Succinate Dehydrogenase

Source

Open in PubMed Open full text

Identifiers

PMID: 25973039
PMCID: PMC4396236

Genes

SDHD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of miR-101 in pheochromocytoma patients with SDHD mutation.PMID 25973039Read ↗

Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical MedicineSemantic proximity Read ↗

Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical MedicineSemantic proximity Read ↗

Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Methylation Quantification As Diagnostic Biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs)Semantic proximity Read ↗

Metastatic Pheochromocytoma and Paraganglioma: Clinicopathological Analysis of 35 CasesSemantic proximity Read ↗

Development and internal validation of a novel predictive model for SDHB mutations in pheochromocytomas and retroperitoneal paragangliomas.Semantic proximity Read ↗

Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Joint application of multiple genes in the diagnosis and pathogenesis of metastatic peochormocytoma/paraganglioma based on bioinformaticsSemantic proximity Read ↗

Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.Semantic proximity Read ↗

Mutations seen among patients with pheochromocytoma and paraganglioma at a referral center from India.Semantic proximity Read ↗

LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.Semantic proximity Read ↗

Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paragangliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.